Bausch Health Companies Inc T.BHC

Alternate Symbol(s): BHC

Healthcare

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

TSX:BHC - Post by User

Bausch Health Companies Inc > BLCO spinoff

<< Previous

Bullboard Posts

Next >>

Comment by borderguyon Apr 08, 2024 12:59pm

194 Views

Post# 35977088

RE:BLCO spinoff

At a ratio of .85 BLCO to BHC shares, a warrant to purchase .85 of a share of BLCO at $4 usd would net BHC over 1.2b usd for debt reduction. Warrants could have an expiry date for early 2025 and would automatically have a value of approximately $10 usd. Exercise price could be adjusted upward if more was needed for debt reduction but this would still allow the shareholders that bought into BHC a chance to participate in the company that they bought into which included Bausch & Lomb. This senerio would leave BHC and their shareholders in a position.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)